Study reveals harmful gut bacteria linked to irregular sleep patterns
New Study from King's College London: Irregular Sleep Patterns Tied to Harmful Gut Bacteria.
List view / Grid view
New Study from King's College London: Irregular Sleep Patterns Tied to Harmful Gut Bacteria.
The University of California underwent a mouse study disclosing underlying sex differences in mice for obesity.
Findings from the Republic of Ireland, in relation to GLP-1 obesity treatment showcase its ability to restore the body’s natural cancer-killing defences.
US researchers discover compound that limits weight gain in mice with a high-sugar diet, by lowering the mitochondrial magnesium.
Japanese researchers discover the mechanism of inhibition of diet-induced obesity in mice by the glucose-dependent insulinotropic polypeptide
The researchers found that the protein Grb10 promotes leptin activity in the brain, opening the possibility of developing Grb10-based new approaches to treat obesity.
Drug-initiated activity metabolomics screening discovers the metabolite myristoylglycine, that converts white fat cells to brown fat cells.
In this article, Drug Target Review’s Ria Kakkad explores the importance of diverse and inclusive samples in genomic studies with Assistant Professor Lindsay Fernández-Rhodes, Pennsylvania State University.
Scientists at the Endocrine Society have found extracellular vesicles may offer new insights into treating endocrine disorders.
A new study by University of Texas Health Science Center at San Antonio has found that boosting liver mRNAs in obese mice reduces appetite and body weight.
Researchers from the University of Pennsylvania may have discovered how to eliminate the risk of weight gain from certain diabetes medications by uncovering the difference between two varieties of a protein.
The study uncovered disordered signalling in the brain's cerebellum, offering a novel therapeutic target for Prader Willi syndrome.
Researchers used obese fruit flies to analyse how gene activities affect triacylglyceride levels, unveiling novel drug targets for obesity.
Treatment with Viking Therapeutics' dual agonists resulted in mean reductions in body weight of up to 27 percent compared to semaglutide-treated animals.
Scientists have discovered a new pharmacological approach to reduce the mitochondrial dysfunction that promotes diet-induced obesity in mice.